TransMedics Group, Inc. (TMDX)

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

TransMedics (TMDX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, TMDX broke out above the 50-day moving average, suggesting a short-term bullish trend.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

ANDOVER, Mass. , Aug. 4, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that the U.S. Food and Drug Administration (FDA) has granted conditional approval of its Investigational Device Exemption (IDE), allowing the company to proceed with the initiation of its Next-Generation OCS ENHANCE Heart trial.

ANDOVER, Mass. , Aug. 1, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on July 28, 2025, TransMedics granted non-qualified stock options to purchase an aggregate of 21,458 shares of its common stock and an aggregate of 14,283 restricted stock units to 14 employees, each as a material inducement for each employee's entry into employment with TransMedics.

TransMedics stock jumps 10.5% as Q2 EPS beats by 91.7%, revenue rises 37.7%, and operating margin expands 1230 basis points.

TransMedics delivered strong Q2 results, with revenue growth remaining robust and margins improving sharply. While there are concerns around the regulatory environment, competition, and seasonality, TransMedics' next-gen heart and lung programs are near-term growth catalysts. I see further upside, but meaningful gains may not materialize until 2026, when the heart and lung opportunity becomes more clear.

Shares of leading organ transplant technology company TransMedics (TMDX 12.66%) rose 15% as of noon ET on Thursday, according to data provided by S&P Global Market Intelligence.

TransMedics Group (TMDX 2.92%), a leader in organ transplant technology, released its second quarter 2025 earnings on July 30, 2025. The company topped Wall Street expectations, posting GAAP revenue of $157.4 million, ahead of the $147.7 million analyst estimate, and delivering GAAP earnings per share (EPS) of $0.92—more than doubling consensus forecasts.

TransMedics Group, Inc. (NASDAQ:TMDX ) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants Waleed Hassanein - Founder, President, CEO & Director Gerardo Hernandez - CFO & Treasurer Conference Call Participants Dorothy Morgan - Gilmartin Group LLC K. Gong - JPMorgan Chase & Co, Research Division Christian Pasquale - Nephron Research Joshua Jennings - TD Cowen, Research Division Samantha Munoz - Piper Sandler & Co., Research Division Zachary Day - Canaccord Genuity Xuesong Wang - Morgan Stanley Suraj Kalia - Oppenheimer & Co. Inc., Research Division David Rescott - Robert W.

The headline numbers for TransMedics (TMDX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

TransMedics (TMDX) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.35 per share a year ago.

Here's our initial take on TransMedics' (TMDX 2.92%) second-quarter financial report.

ANDOVER, Mass. , July 30, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2025.

TransMedics Group reports its Q2 earnings after the bell. Wall Street current expectations stand at: Revenue: $147.74 million Adjusted EPS: $.43 We'll be updating this live blog with updates during the trading day and then once earnings hit the newswires will post a flurry of news and analysis.